Star cell injection for generalized myasthenia gravis
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial tests whether an injection of special immune cells called STAR-T cells can help people with generalized myasthenia gravis. It is for those whose symptoms are moderate to severe and haven't improved enough after at least two standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 65 years old
- Have a confirmed diagnosis of generalized myasthenia gravis (GMG) with moderate to severe symptoms
- Have tried at least two different immunosuppressant or biologic medications without enough relief
- Have stable organ function, like normal blood counts, liver and kidney function
- Agree to use effective birth control during the study and for a period after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy (CAR-T cells) for people with generalized myasthenia gravis. It aims to reduce symptoms and improve daily life by targeting and destroying faulty immune cells.
This trial tests a new CAR-T cell therapy (YTB323) for people with generalized myasthenia gravis that hasn't been well-controlled by standard treatments. The goal is to see if it can safely improve symptoms and change how the immune system attacks the nerves.
This study tests a new drug called SHR-2173 to help people with generalized myasthenia gravis (a condition where muscles weaken because the immune system blocks communication between nerves and muscles). The drug is designed to work with treatments you're already taking to improve muscle strength and reduce symptoms.
This trial tests a new medication called Telitacicept for people with generalized myasthenia gravis (gMG). The goal is to see if it can reduce muscle weakness and improve daily function. You may be able to join if you have moderate to severe symptoms and have not had recent thymoma or other serious health issues.
This trial tests a new drug called HN2301 for patients with generalized myasthenia gravis (a disease where the immune system weakens muscles) who have not responded well to standard treatments. The goal is to see if HN2301 can safely improve muscle strength and daily function.
This trial tests multiple treatment combinations for people with myasthenia gravis (MG), a condition that causes muscle weakness. It aims to find safer and more effective options by comparing different therapies.
Hear when a new Generalized Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.